Edition:
United States

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

27.90USD
21 Jul 2017
Change (% chg)

$-0.60 (-2.11%)
Prev Close
$28.50
Open
$28.80
Day's High
$28.80
Day's Low
$27.55
Volume
75,940
Avg. Vol
88,256
52-wk High
$29.45
52-wk Low
$7.68

Latest Key Developments (Source: Significant Developments)

Intersect ENT says U.S. FDA has accepted NDA for its investigational Sinuva steroid releasing sinus implant
Monday, 22 May 2017 07:00am EDT 

May 22 (Reuters) - Intersect Ent Inc :Intersect ENT Inc says U.S. FDA has accepted new drug application for company's investigational Sinuva™ steroid releasing sinus implant.Intersect ENT Inc says U.S. FDA set a PDUFA target action date of January 7, 2018.  Full Article

Intersect Ent Q1 revenue $20.5 million
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Intersect Ent Inc :Intersect Ent reports first quarter 2017 results.Q1 revenue $20.5 million versus i/b/e/s view $19.4 million.Sees q2 2017 revenue $22.5 million to $22.7 million.Sees fy 2017 revenue $89 million to $91 million.Qtrly net loss per share, basic and diluted $0.23.Q1 earnings per share view $-0.25, revenue view $19.4 million -- Thomson Reuters I/B/E/S.Q2 revenue view $21.7 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease
Wednesday, 8 Mar 2017 08:00am EST 

Intersect ENT Inc : Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease . Intersect ENT - Trial met both co-primary efficacy endpoints, demonstrating a statistically significant reduction in nasal congestion and polyp burden .Intersect ENT Inc - Submission supported by four clinical studies evaluating safety and effectiveness.  Full Article

Intersect Ent Q4 loss per share $0.17
Tuesday, 28 Feb 2017 04:05pm EST 

Intersect Ent Inc : Intersect ENT reports fourth quarter and full year 2016 results . Q4 loss per share $0.17 . Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S . Sees q1 revenue $19 million to $19.5 million . Sees fy 2017 revenue $87 million to $89 million . Q4 revenue $24.2 million versus i/b/e/s view $23.5 million . Intersect ent inc says expects full year 2017 gross margin of approximately 83%-84% and operating expenses of approximately $96-$98 million .Fy2017 earnings per share view $-0.69, revenue view $87.6 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT says FDA approves steroid releasing implant Propel Contour
Friday, 24 Feb 2017 08:00am EST 

Intersect Ent Inc : Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses . Intersect ENT Inc - expects to launch propel contour broadly in Q2 of 2017 and maintains its previously stated 2017 revenue guidance of $87-$89 million .FY2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect Q2 loss per share $0.21
Tuesday, 2 Aug 2016 04:05pm EDT 

Intersect ENT Inc : Q2 loss per share $0.21 . Q2 revenue $19.3 million versus I/B/E/S view $18.8 million . Intersect ENT reports second quarter 2016 results . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Sees Q3 2016 revenue about $17.8 million . Fy2016 revenue view $78.3 million, q3 revenue view $18.4 million -- Thomson Reuters I/B/E/S .Expects full year revenue at low end of previous guidance range of $78 million-$80 million.  Full Article

Intersect ENT announces FDA submission of NOVA
Monday, 1 Aug 2016 07:58am EDT 

Intersect ENT Inc :Intersect ENT announces FDA submission of NOVA bioabsorbable steroid releasing implant for patients with chronic sinus disease.  Full Article

BRIEF-Intersect ENT prelim Q2 revenue $19.3 mln
Monday, 18 Jul 2016 08:00am EDT 

Corrects third bullet to preliminary revenue, not reported revenue.Intersect Ent Inc : Says company's Chief Commercial Officer Chas McKhann is departing for personal reasons . Announces preliminary Q2 revenue and business update .Q2 preliminary revenue $19.3 million versus I/B/E/S view$18.8 million.  Full Article

Intersect ENT Inc reaffirms FY 2016 revenue guidance
Thursday, 5 May 2016 04:05pm EDT 

Intersect ENT Inc:Continues to project revenue for FY 2016 in the range of $78-$80 million.  Full Article

Intersect ENT Inc gives Q4, FY 2015 revenue guidance; gives FY 2016 revenue guidance
Monday, 11 Jan 2016 04:05pm EST 

Intersect ENT Inc:Anticipates revenue for the Q4 2015 in the range of $18.6 to $18.8 million.Anticipates revenue for the FY 2015 of approximately $61.4 to $61.6 million.Continues to expect significant revenue growth in FY 2016 and forecasts revenue to be between $78 and $80 million.  Full Article

BRIEF-Intersect Ent Q1 revenue $20.5 million

* Q1 earnings per share view $-0.25, revenue view $19.4 million -- Thomson Reuters I/B/E/S